Thomas Samdal Named CFO of Benchmark Genetics

Benchmark Genetics has announced the appointment of Thomas Samdal as its new Chief Financial Officer (CFO), effective April 1. Samdal joins the executive management team, taking over from Jon Crowther, who is set to retire after a brief transition period.

Professional Background

Before joining Benchmark Genetics, Samdal served as CFO at the research institute NORCE, where he oversaw the entire finance function, which included responsibilities for reporting, financing, and sustainability reporting, among other corporate duties. His rich experience spans several CFO roles across multiple companies, along with extensive experience in investment activities and auditing.

Educational Qualifications

Samdal holds a Master of Science in Economics and Business Administration from the Norwegian School of Economics (NHH), alongside a Master’s degree in Accounting and Auditing. With nearly 20 years of experience in auditing, corporate finance, and financial leadership, he brings a robust combination of financial acumen and operational insight. Furthermore, he has significant experience in private equity, both as an Investment Manager and as a CFO for PE-backed companies.

CEO’s Remarks

CEO Kristian Botnen expressed enthusiasm about Samdal’s appointment, stating, “We are very pleased to welcome Thomas to the team. His strong professional profile and broad experience from both commercial companies and research environments align perfectly with our ongoing efforts to solidify Benchmark Genetics’ status as a global leader in aquaculture genetics. His capability to link strategy with operational execution will be crucial for our future growth.”

Looking Ahead

Samdal is eager to contribute to Benchmark’s growth as the company continues its journey as an independent firm under the ownership of Novo Holdings. He remarked, “Benchmark Genetics plays a key role in the global aquaculture value chain, where genetics is foundational for both sustainability and profitability. I am motivated by the opportunity to enhance a more efficient and sustainable food system. Joining the company at this pivotal time excites me, as we aim to scale and develop further. A crucial aspect of my role will be to ensure that the finance function actively supports our core business and enables achievement of our strategic objectives.”

Commitment to Growth

In the past year, Benchmark Genetics has established itself as an independent entity under the umbrella of Novo Holdings and has laid out an ambitious strategy for growth in genetic and genotyping services on a global scale.

Image: Benchmark Genetics